Healthcare data analytics company Komodo Health is partnering with Anervea.ai, an AI-native life sciences technology company, to develop and deploy an AI-powered suite of applications on Komodo's MapLab Enterprise platform.
Anervea.ai aims to use Komodo's healthcare map to improve stages of clinical research and trial execution and allow life sciences teams to speed up data-driven clinical development via AI-powered healthcare intelligence.
Life sciences companies that deploy the Anervea.ai offering through MapLab Enterprise will have the ability to accelerate strategic intelligence across the development life cycle.
Some examples include "predictive modeling of clinical trial success across protocol variants and geographies; early forecasting of market success based on real-world adoption and referral patterns; simulation of launch pricing and reimbursement scenarios using analogs and payer data; real-time insights to inform regulatory strategy, trial feasibility and portfolio risk; and intelligent recommendations on protocol design, site selection and diversity optimization."
According to Komodo Health, Anervea.ai is the first partner in Komodo's ecosystem to construct licensable, AI-native tools directly on top of Komodo's healthcare intelligence platform.
"Komodo’s Healthcare Map gives us the depth, scale and reliability needed to bring real-world intelligence to the heart of clinical development," Ayush Atul Mishra, founder and CEO of Anervea.ai, said in a statement.
"Our vision is to help clinical and research and development teams move with speed and precision by embedding AI into the workflows that matter most – from trial design to execution. This partnership marks a major step toward that goal."
Miles Ennis, chief revenue officer for Komodo Health, said, "By enabling Anervea.ai to build its powerful AI-native tools directly on our trusted MapLab Enterprise platform, we are empowering Life Sciences organizations to not only make more informed decisions, but fundamentally accelerate and optimize clinical trial design and execution, ultimately benefiting patients."
THE LARGER TREND
In May, Komodo Health partnered with Nasdaq Data to provide hedge funds, private equity and venture capital firms with an in-depth view into the pharmaceutical and U.S. healthcare industries through the Nasdaq Medical Claims Insights (NMCI) dataset.
Nasdaq Data used Komodo's Healthcare Map, which uses real-world data to analyze payer and provider trends, disease incidence, patient care and prescribing patterns.
NMCI will enable market participants to track trends in the pharmaceutical and healthcare industries, help forecast drug- and company-level revenues, analyze shifts in market shares, and identify emerging drugs and companies.
In 2023, Komodo Health hired Vikas Mehta as its chief financial officer. Mehta previously held the position of CFO at Nike Direct during the COVID-19 pandemic and had finance-related roles at Walmart, Microsoft and PayPal.
In 2022, Komodo Health laid off 9% of its staff as part of a larger restructuring of its business.
The company said that the pandemic created opportunities for the analytics company, Komodo’s cofounders Arif Nathoo and Web Sun wrote in a message to employees that was also posted on LinkedIn. The company said that the economic environment forced its customers to seriously consider their purchasing decisions.
